Genscript Biotech Corporation reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was USD 391.31 million compared to USD 309.59 million a year ago. Net loss was USD 93.58 million compared to USD 135.51 million a year ago.

Basic loss per share from continuing operations was USD 0.0444 compared to USD 0.0648 a year ago. Diluted loss per share from continuing operations was USD 0.0444 compared to USD 0.0648 a year ago.